Clinical Focus

  • Cancer > Cutaneous (Dermatologic) Oncology
  • Dermatology
  • Inpatient Dermatology Consultation
  • Cutaneous complications of cancer therapy and hematopoietic stem cell transplantation

Academic Appointments

Administrative Appointments

  • Director, Inpatient Dermatology Consultation Service, Stanford Dermatology (2012 - Present)

Professional Education

  • Board Certification: Dermatology, American Board of Dermatology (2012)
  • Medical Education:Yale University School of Medicine (2007) CT
  • Residency:Stanford University - Dept of Dermatology (2012) CA
  • Chief Resident, Stanford Dermatology, Dermatology (2012)
  • Residency, Stanford Dermatology, Dermatology (2012)
  • Internship:Yale - New Haven Hospital (2008) CT

Research & Scholarship

Clinical Trials

  • A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma Recruiting

    The purpose of this study is to assess the safety and tolerability of escalating doses of SD-101 in combination with pembrolizumab in patients with metastatic melanoma.

    View full details

  • Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkins Lymphoma Recruiting

    The purpose of this study is to determine which doses of Urelumab and Nivolumab are safe and tolerable when they are given together.

    View full details

  • Modified Dakin's Solution in Reducing Radiation-Induced Dermatitis in Patients With Head and Neck Cancer Undergoing Radiation Therapy Recruiting

    This randomized phase III trial studies how well modified Dakin's solution works in reducing radiation-induced dermatitis, a common skin reaction to radiation therapy, in patients with head and neck cancer undergoing radiation therapy. Modified Dakin's solution may reduce inflammation in the body, which may prevent or reduce dermatitis after radiation therapy.

    View full details


All Publications

  • Management of Dermatologic Complications of Lung Cancer Therapies. Current treatment options in oncology Pugliese, S. B., Neal, J. W., Kwong, B. Y. 2015; 16 (10): 368-?


    In recent years, oncogene-directed targeted agents and immunotherapies have expanded the treatment armamentarium for advanced lung cancer and, in particular, non-small cell lung cancer (NSCLC). Along with extended survival, these agents are accompanied by a host of cutaneous complications that affect the skin, hair, and nails. These skin complications range from the well-characterized papulopustular (acneiform) eruption of the epidermal growth factor receptor (EGFR) inhibitors to the emerging characterization of lichenoid skin eruptions seen during treatment with antibodies targeting the programmed cell death protein 1 (PD-1) and programmed cell death protein 1 ligand (PD-L1). When promptly recognized and accurately diagnosed, most cutaneous adverse events can be managed with supportive treatments, avoiding the need to interrupt antitumor therapy. Furthermore, preemptive management of skin problems can lead to significantly decreased severity of many cutaneous complications of these therapies. We encourage close collaboration between dermatologists and oncologists to better characterize cutaneous toxicity, select appropriate management, and avoid unnecessary dose reduction or discontinuation while simultaneously improving patient quality of life.

    View details for DOI 10.1007/s11864-015-0368-y

    View details for PubMedID 26338208

Stanford Medicine Resources: